Lancefield group C and group G streptococci, though uncommon pathogens, have been reported to cause a variety of serious infections (7, 8, 13, (15) (16) (17) . These organisms are usually susceptible to penicillin (3, 4) , but poor responses to penicillin therapy have been described in serious infections (endocarditis and septic arthritis) (2, 5) . Tolerance to penicillin G, cephalothin, and vancomycin has been reported (9, 10) . Though the clinical significance of tolerance is not clear, experimental and clinical evidence indicates that it may adversely affect the response to therapy of endocarditis (11, 12) .
We tested 44 strains (25 group C and 19 group G) in this study. All strains were human isolates and were identified serologically by the Phadebact coagglutination reaction (6) . Two (Table 2 ). The newer semisynthetic penicillins and the third-generation cephalosporins, except moxalactam, exhibited excellent activity against both organisms, with MICs and MBCs ranging from 0.03 to 1 ,ug/ml. Good activity was also observed with erythromycin.
The organisms exhibited moderate susceptibility to maxolactam, with the 90%o MIC being 8
,ug/ml. This is similar to the susceptibility of group B streptococci which require between 8 and 16 ,ug/ml for inhibition. Since moxalactam is currently not recommended for group B infections (14) , particularly those of the central nervous system, it would seem prudent to extend the same reservation to group C and group G streptococcal infections.
Penicillin retains its place as the drug of choice in infections due to group C and group G streptococci. Tolerance, however, has been demonstrated and may on occasion account for the slow response seen in seriofis infections. We did not observe cross-tolerance, and several alternatives to penicillin are available, including newer semisynthetic penicillins and third-generation cephalosporins. In patients allergic to penicillin, vancomycin and erythromycin are adequate substitutes, but careful testing of inhibitory and bactericidal activity may still be necessary.
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